News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.
1 hr ago | TheStreet.com
Separately, TheStreet Ratings team rates PFIZER INC as a "buy" with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation: "We rate PFIZER INC a BUY.
Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
Alan Auerbach specializes in testing drugs that Big Pharma doesn't want anymore, and that has made him a billionaire.
JNJ reported a 2.4% increase in its consumer segment revenue, led by a 9% rise from over the counter drugs, including Tylenol.
This Eye-Popping Chart Of Ex-US Companies Shows Why People Are Freaking Out About 'Tax Inversions' A tax inversion is a corporate merger strategy that involves a company based in one country, say the U.S., acquires another company based somewhere else, say the U.K., and following the deal moves its tax base to enjoy a lower corporate tax rate.
Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.
President Barack Obama is taking direct aim at the rising number of U.S. companies using international mergers to relocate their headquarters overseas in an effort to avoid paying U.S. corporate taxes.
Calls are the options of choice on Pfizer Inc. today, with roughly 10,000 calls and 3,500 puts changing hands so far.
Bristol-Myers Squibb Co. , the maker of the anti-psychotic drug Abilify, reported second-quarter profit that topped analysts' estimates on sales of its cancer medicine Yervoy and blood thinner Eliquis.
Our regular readers know that we have been using the idea of buying on the dips and searching for value while investing in this bull market the past few years.
Lawyers who battled Pfizer Inc. for more than a decade over women's cancers linked to the company's Prempro menopause drug settled a rare public dispute over $62 million in fees.
ATRA, a clinical-stage biopharmaceutical firm, engaged in the development of treatments for muscle wasting conditions, plans to raise $75.0 million in its upcoming IPO.
The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Wednesday, with over 377,000 shares traded versus three month average volume of about 101,000.
Although we did not see a positive neratinib ExteNET outcome in adjuvant breast cancer as a complete surprise, we believe the magnitude of benefit is among best-case scenarios that could be envisioned.
Updated: Mon Jul 28, 2014 08:08 am
Copyright © 2014 Topix LLC